Log in
Sign up
Golden has been acquired by ComplyAdvantage.Read about it here ⟶
‌

US Patent 11291667 Combination therapy involving diaryl macrocyclic compounds

Patent 11291667 was granted and assigned to Turning Point Therapeutics on April, 2022 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributorsActivity

The present disclosure relates to methods and compositions for treating cancer with a diaryl macrocycle in combination with at least one other cancer therapeutic, such as an EGFR inhibitor.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 11291667 Combination therapy involving diaryl macrocyclic compounds

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo